Anecdotal animal and clinical data have all suggested that cannabis or cannabinoids may ameliorate pain, spasticity, muscle spasms, and other symptoms in MS.1 ! 8 UK doctors have been barred from prescribing cannabis preparations since 1971 under the Misuse of Drugs Act. Cannabis contains more than 60 different oxygen-containing aromatic hydrocarbon compounds unique to the plant, known as cannabinoids.
Here is the full scientific article if you wish to download it.
The principal psychopharmacological component in cannabis is D9-tetrahydrocannabinol, 11 but other derivatives may have therapeutic or synergistic potential. Cannabidiol is the most promising of these, especially as it is nonpsychoactive and may modulate the intoxicating and/or memory effects of THC.12 The majority of cannabis available illicitly in the UK contains significant amounts of THC and CBD. Recently, standardized whole plant cannabis medicinal extracts have become available for clinical research.
15 Single case-crossover studies have demonstrated that these CBMEs have the potential to reduce previously intractable symptoms, including pain, spasms, and spasticity in patients with MS and other neurological conditions16 with low levels of intoxication.
In conclusion, the results of this study suggest that CBME is an effective treatment for spasticity associated with MS. The use of gradual self-titration of the dose allowed most people to achieve benefit without unduly troublesome side effects. Taking into account the results of the CAMS trial and our own preliminary study it is evident that further studies to clarify the precise role of CBME for people with MS are indicated, especially its potential for controlling several symptoms at the same time.
More studies do need to be carried out and evaluated to get a better understanding, however, we are one step closer to understand cannabis as a method of treating Multiple Sclerosis (MS). If you wish to use it, consult a medical professional.